Can't recall who posted the Lalezari interview, but THANK YOU. Great interview. FDA's shameful behavior is beyond understanding. Picking winners without the data to support those decisions is unforgivable. Leronlimab's safety profile should have prompted a rubber stamp from FDA to get trials started immediately and it should have been and should still be front and center with FDA's staff.